Novartis’ Tasigna Joins Bristol’s Sprycel For CML Resistant To Gleevec
Executive Summary
Novartis expects Tasigna (nilotinib) will be used in the small number of chronic myeloid leukemia patients with advanced resistant disease who already have received high dose Gleevec (imatinib), and as a result, is pricing the product on par with the 800 mg dose of Gleevec typically used for such patients - about $5,700 per month